Category: 23256-42-0

On June 30, 2017, Podesvova, Lucie; Huang, Huan; Yurchenko, Vyacheslav published an article.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the article was Inducible protein stabilization system in Leishmania mexicana. And the article contained the following:

Targeted regulation of protein levels is an important tool to investigate the role of proteins essential for cell function and development. In recent years, methods based on the Escherichia coli dihydrofolate reductase destabilization domain (ecDHFR DD) have been established and used in various cell types. ecDHFR DD destabilizes the fused protein of interest and causes its degradation by proteasomes, unless it is stabilized by a specific ligand, trimethoprim. In this work we developed an inducible protein stabilization system in Leishmania mexicana based on ecDHFR DD. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to protein stabilization system leishmania dihydrofolate reductase, leishmania mexicana, protein stabilization, trimethoprim, ecdhfr, Enzymes: Structure-Conformation-Active Site and other aspects.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Grey, Daphne; Hamilton-Miller, J. M. T. published an article in 1977, the title of the article was Sensitivity of Pseudomonas aeruginosa to sulfonamides and trimethoprim and the activity of the combination trimethoprim: sulfamethoxazole.Computed Properties of 23256-42-0 And the article contains the following content:

P. aeruginosa strains from urinary infections were resistant or only moderately sensitive to sulfadiazine [68-35-9], sulfamethoxazole (I) [723-46-6], sulfadimidine [57-68-1], or trimethoprim lactate (II lactate) [23256-42-0], but a marked synergy between I and II was noted with the moderately sensitive strains. Thus, therapeutically attainable urinary levels of these drugs (which were ineffective individually) were quite inhibitory to P. aeruginosa when used in combination. The min. inhibitory concentrations of I and II when used in combination suggested that disks containing I and II at a 1:2 ratio would be more appropriate for determining the drug susceptibility of urinary pathogens than the usual 1:20 ratio. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Computed Properties of 23256-42-0

The Article related to sulfonamide trimethoprim pseudomonas sensitivity, urine pseudomonas trimethoprim sulfamethoxazole, Biochemical Interactions: Microbial Systems and other aspects.Computed Properties of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Thirkell, D.; Blankson, M. published an article in 1981, the title of the article was The speciation of coliform genera from above and below a sewer outfall and their susceptibilities to antimicrobial agents.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate And the article contains the following content:

The occurrence of coliforms in a small water course increased by a factor of 36 below the outfall of a sewage treatment plant. Speciation of the bacteria from above and below the sewer outfall showed that Escherichia coli and Enterobacter species predominated. Drug-resistance levels were significant in microorganisms from both sampling sites, and the occurrence of a significant number of multiple-resistant microorganisms, particularly E. coli, is reported. Both E. coli and Enterobacter species from below the sewer outfall showed a statistically significant increase in resistance to ampicillin [69-53-4] as compared with isolates from above the outfall, and E. coli from below the outfall also showed a statistically significant increase in resistance to sulphamethoxazole [723-46-6]. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to coliform bacteria sewage antibiotic sensitivity, taxonomy coliform bacteria sewage, Biochemical Interactions: Microbial Systems and other aspects.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Hamilton-Miller, J. M. T.; Grey, Daphne published an article in 1975, the title of the article was Resistance to trimethoprim in klebsiellae isolated before its introduction.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate And the article contains the following content:

In vitro 6 of 12 strains of Klebsiella aerogenes or K. ozaenae were resistant to trimethoprim lactate (I lactate) [23256-42-0], whereas all 12 strains were resistant to sulfamethoxazole [723-46-6]. All of these 12 strains were isolated and freeze-dried (1961-64) prior to clin. use of I. Of the 6 I-resistant strains, 5 were also resistant to tetracycline, chloramphenicol, and streptomycin. No evidence was found for R-factor involvement in I resistance. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to trimethoprim resistance klebsiella, sulfamethoxazole resistance klebsiella, Biochemical Interactions: Microbial Systems and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 7, 2010, Dong, Wei; Li, Xiaowen; Sun, Zhiliang published a patent.HPLC of Formula: 23256-42-0 The title of the patent was Long-acting antibacterial medicinal water-in-oil emulsion and its preparation method. And the patent contained the following:

The title emulsion is composed of water phase, oil phase, emulsifying agents and stabilizers. The oil phase is white oil 7# or 15#. The water-phase emulsifying agent is tween 80 and the oil-phase emulsifying agent is span 80. The emulsion is prepared by adding water-phase stabilizer into water at 40-45°, cooling to room temperature, dissolving antibacterial drug, adding tween 80, stirring to obtain water phase, adding 65-130° white oil 7# or 15# into oil-phase stabilizer, stirring, cooling to 50-60°, dissolving span 80, stirring to obtain oil phase, mixing water phase with oil phase, emulsifying and sterilizing. The antibacterial drug can be slowly released from the emulsion. The emulsion may be used as veterinary medicine for preventing and treating animal diseases in breeding field. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).HPLC of Formula: 23256-42-0

The Article related to veterinary antibacterial drug sustained release emulsion, Pharmaceuticals: Formulation and Compounding and other aspects.HPLC of Formula: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 12, 1976, Alvan, George E.; Holstius, Elvin A. published a patent.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Solution containing trimethoprim, sulfacetamide, and polymyxin. And the patent contained the following:

Ophthalmic solutions for the treatment of microbial (especially bacterial) infections containing sulfacetamide (I) [144-80-9], a trimethoprim salt, and polymyxin salt were reported. E.g., an ophthalmic solution contains I 0.50, trimethoprim hemisulfate [56585-33-2] 0.123 g, polymyxin B sulfate [1405-20-5], 1,200,000 units, thimerosal 0.001, NaCl 0.83 g, and water for injection to 100.00 ml. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to trimethoprim sulfacetamide polymyxin ophthalmic solution, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 10, 2015, Wang, Yuwan; Dai, Xiaoxi; Pan, Zhende; Ren, Yanan; Li, Lei; Li, Ying; Weng, Zhifei; Shen, Li published a patent.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Preparation method of emulsifiable oleaginous injection containing hydrophilic medicine. And the patent contained the following:

The title emulsifiable oleaginous injection containing hydrophilic medicine is composed of hydrophilic medicine (such as valnemulin hydrochloride, tiamulin fumarate, etc.) 80-200g, poloxamer 188 20-60g, soybean phospholipids 1-5g and injection soybean oil or soybean oil/ethyl oleate to 1L. The preparation method of the emulsifiable oleaginous injection includes sterilizing injection soybean oil by heating, cooling, adding other materials and sand milling. Emulsification of emulsifiable oleaginous injection containing hydrophilic medicine occurs, when the emulsifiable oleaginous injection contacts to water, forming a emulsion or emulsion/oil system, thus reducing the release rate of drug. The emulsifiable oleaginous injection has large drug load, good biocompatibility, good stability and easy preparation method. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to hydrophilic medicine emulsifiable oleaginous injection, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 17, 2010, Xu, Kefu published a patent.Application of 23256-42-0 The title of the patent was Compounded amoxicillin soluble powder for treating duck serositis and preparation method thereof. And the patent contained the following:

The compounded amoxicillin soluble powder is prepared from (by weight%) amoxicillin 2-20, sulfamonomethoxine sodium 2-20, trimethoprim lactate 0.4-4, diclofenac sodium 2-10, anhydrous sodium carbonate 1-8, and anhydrous glucose as balance. The preparation method comprises grinding each material, and then mixing for 1 h. By cooperative effect between amoxicillin and sulfamonomethoxine sodium, the drug resistance of Riemerella anatipestifer is greatly reduced, the pathogen-resisting ability is increased, and secondary infection can be also inhibited. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application of 23256-42-0

The Article related to amoxicillin soluble powder duck serositis veterinary, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 20, 2013, Zhou, Qingfu; Liu, Wenli published a patent.Electric Literature of 23256-42-0 The title of the patent was Method for preparation of composite gentamicin sulphate composition for treating poultry diarrhea. And the patent contained the following:

Title composition is prepared from gentamicin sulfate 5-10, ciprofloxacin hydrochloride 10-15, berberine hydrochloride 10-20, trimethoprim lactate 5-9, and anhydrous glucose 46-70 weight parts. The preparation process includes uniformly mixing gentamicin sulfate, ciprofloxacin hydrochloride and anhydrous glucose (15-25 weight parts) for 5-10 min, uniformly mixing berberine hydrochloride, trimethoprim lactate and anhydrous glucose (15-29 weight parts) for 5-10 min, merging the two mixture, and mixing with residual anhydrous glucose for 10-15 min to obtain the composite gentamicin sulfate composition The composite gentamicin sulfate composition has advantages of simple preparation process and good therapeutic effect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Electric Literature of 23256-42-0

The Article related to gentamicin sulfate poultry diarrhea veterinary drug, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2020, there was a patent about pharmaceutical powders, synergism.Category: pyrimidines The title of the patent was Florfenicol soluble powder powder medicine. And the patent contained the following:

The present invention discloses a soluble powder medicine of florfenicol, which relates to the tech. field of veterinary medicine. The composition of florfenicol soluble powder powder medicine is: florfenicol, anhydrous citric acid, trimethoprim lactate and anhydrous glucose. The florfenicol soluble powder powder medicine of the present invention can be quickly dissolved in water to achieve the purpose of being soluble, and has the advantages of convenient administration and rapid onset of action. The combined use of florfenicol and a synergist enhances the therapeutic effect of the overall powder, improve the efficacy. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Category: pyrimidines

The Article related to florfenicol citric acid trimethoprim lactate powder, Pharmaceuticals: Formulation and Compounding and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia